Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases
Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Year Invested: 2013
Location: Cambridge, Mass.